You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
Innate and adaptive immunity contribute to the anti-tumor mechanisms of action of OncoVEXmGM-CSF
Free
  1. Keegan Cooke1,
  2. Karen Fitzgerald2,
  3. Becky Yang3,
  4. Petia Mitchell1,
  5. Juan Estrada4,
  6. Beltran Pedro5 and
  7. Achim K Moesta2
  1. Aff1 grid.417886.40000000106575612Amgen Thousand Oaks CA USA
  2. Aff2 grid.417886.40000000106575612Amgen Inc. South San Francisco CA USA
  3. Aff3 grid.417886.40000000106575612Amgen Inc. South CA USA
  4. Aff4 grid.417886.40000000106575612Amgen Inc. Thousand Oaks CA USA
  5. Aff5 grid.417886.40000000106575612Amgen, Inc. Thousand Oaks CA USA

https://doi.org/10.1186/2051-1426-3-S2-P338

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Background

    Talimogene laherparepvec, an investigational oncolytic immunotherapy, is a modified herpes simplex virus type-1 (HSV-1) designed to selectively replicate in tumors and to initiate a systemic immune response to target cancer cells. Intralesional administration of talimogene laherparepvec is intended to result in oncolysis within injected tumors, with lytic cell destruction promoting the local release of progeny virus and tumor derived antigens. GM-CSF, a product of the viral transgene, is also produced locally such that it can recruit and stimulate antigen presenting cells to further enhance systemic anti-tumor immune response.

    Methods

    In a retrospective analysis of a Phase III melanoma trial investigators found that about two-thirds of the lesions injected with talimogene laherparepvec shrank 50% or more. Among uninjected tumors similar responses were seen in one third of lesions of the skin and lymph nodes and about a sixth of uninjected visceral lesions providing an indication that the treatment is triggering systemic immune effect.

    To further dissect the mechanism of action underlying innate and adaptive immunity following viral administration, a talimogene laherparepvec expressing murine GM-CSF (OncoVEXmGM-CSF) was employed in syngeneic tumor models (A20 and CT26).

    Results

    When administered intratumorally (3 doses of 5x10^6 PFU) OncoVEXmGM-CSF induces tumor regressions in the injected lesion, but also results in significant anti-tumor effects in a contralateral (uninjected) lesion and marked size increases in injected tumor draining lymph nodes. Flow cytometric profling, gene expression analysis, and IHC revealed infiltration of T cells, innate effector cells and antigen presenting cells in tumors and draining lymph nodes. Innate immune responses in the injected tumor are characterized by the induction of Interferon response gene signatures and result in the systemic release of proinflammatory cytokines. These effects are, at least in part, dependent on STING activity, with in vitro functional assays supporting direct agonism of this pathway by the virus. Systemic anti-tumor responses appear to be T cell driven: T cells expressed higher levels of activation markers as early as 2 days post-treatment in injected tumors, with evidence of T cell activation in contralateral lesion by day 7. To elucidate anti-viral and anti-tumor T cell responses, ex vivo re-challenge assays were performed using splenocyte- and draining lymph node-derived T cells following treatment with OncoVEXmGM-CSF; viral treatment increased systemic anti-tumor immunity and showed induction of anti-viral responses.

    Conclusions

    In conclusion, in vitro and in vivo observations suggest that intratumoral injection of OncoVEXmGM-CSF activates multiple immune-mediated mechanisms of action, leading to T cell activation and induction of anti-tumor immunity in mice.